The aim of the study was to determine the association between previous stroke and mortality after coronavirus disease 2019 (COVID-19) according to sex, age groups, and stroke subtypes.

This overview attempts to give a thorough insight into SARS-CoV-2 neurological infection and highlights the possible mechanisms leading to the neurological manifestations observed in infected patients.

The goal of this study is to update the pooled prevalence of COVID-19 infection in patients with Parkinson's disease.

The objective of this study was to review the literature and provide a summary of COVID-19-related neurologic and neuro-ophthalmic complications.

This review gathers information from 64 reports of de novo movement disorders developing after/during infection with SARS-CoV-2

This study aimed at (1) assessing LTM functioning in post-infectious SARS-CoV-2 patients by accounting for premorbid and disease-related confounders and (2) exploring its cognitive etiology.

In this study, the authors retrospectively evaluated patients admitted to their clinic and diagnosed with VZV-ND during the COVID-19 vaccination campaign (January–April 2021) and in the same months in the previous two years.

CogEx is an international, multicentre MS dual-intervention (cognitive rehabilitation, aerobic exercise) randomized, controlled rehabilitation trial confined to people with progressive disease.

This retrospective observational study aims to explore associations between PM2.5 and COVID-19 severity amongst PwMS.

In this single-centre prospective case study patients with neurological autoimmunity in temporal association (≤6 weeks) with SARS-CoV-2 vaccinations and without other triggers are reported.

The aim of this study is to compare COVID-19–related outcomes collected in an Italian cohort of patients with MS with the outcomes expected in the age- and sex-matched Italian population.

The objective of this study was to investigate the impact of COVID-19 on children receiving immunosuppressive therapies for neuroimmunologic disorders.

One year on from the onset of the COVID-19 pandemic, the authors aimed to summarise the frequency of neurological manifestations reported in COVID-19 patients and investigate the association of these manifestations with disease severity and mortality.

In this article the authors have developed a postmortem bedside surgical procedure to harvest endoscopically samples of respiratory and olfactory mucosae and whole olfactory bulbs.

The objective of this randomised, double blind, placebo controlled trial was to determine if inhaled and intranasal ciclesonide are superior to placebo at decreasing respiratory symptoms in adult outpatients with COVID-19.